The aim of study is to prevent intraventricular hemorrhage by magnesium sulfate in very low birth weight neonates (birth weight ≤1500 grams). In double blind clinical trial 140 very low birth weight (VLBW) will elect. All babies who admit to Imam Reza NICU with birth weight ≤1500 grams and gestational age ≤ 34 weeks included. The babies with major malformation, infection, hemostatic disorder, sever cardio respiratory failure, asphyxia and resuscitation in delivery room will exclude. They randomly will divide in two groups by coin. Intervention group will receive 50% magnesium sulfate, 2.5-5 mg/kg/ day magnesium element via intravenous injection over 15-20 minutes for 3 days. The control group will not take anything. All babies will have a cranial sonography in 24 to 48 hours of life if it be normal will participate in the study. The sonography will repeat at the end of week 1,2and 3 after birth by radiologist who does not knows about intervention. Gestational age, birth weight, sex, five minute apgar score, surfactant usage, blood sugar, anemia, seizure, infection, acidosis, hypoxia, pneumothorax and hypertension will record. Magnesium level will check in day 4 at the end of treatment. Complication of intravenous sulfate magnesium injection includes hypotension, Sinoauricular or atrioventricular conduction.